Astellas and Minovia enter deal for mitochondrial cell therapies
The alliance plans to develop treatments that can transfer healthy mitochondria to restore the tissues of the patients.
Deals
Takeda and Frazier to launch HilleVax for norovirus vaccine development
The newly launched biopharma company will gain rights to the vaccine candidate in global markets,...
Deep Genomics raises $180m to advance drugs for genetic diseases
The proceeds will aid in extending the company’s AI Workbench and expanding its pipeline to...
Amgen to acquire biotech company Teneobio for up to $2.5bn
Teneobio will receive an upfront cash payment of $900m at the closing of the deal...
AbbVie and Calico extend partnership on drugs for age-related diseases
The companies will co-invest nearly $1bn for the alliance, which will extend next year until...
Dyadic and Rubic to develop Covid-19 vaccines for African markets
Rubic will pay a licencing fee that is equal to a proportion of product sales or a vaccine fee on a per-dose basis to Dyadic.
PerkinElmer agrees to acquire antibody maker BioLegend for $5.25bn
On acquisition, BioLegend’s campus in San Diego will be turned into PerkinElmer’s CoE to develop reagent content.
Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug
As per the agreement, Pfizer will invest $350m in Arvinas, representing about 7% of the stake.
AstraZeneca concludes Alexion acquisition for $39bn
Alexion’s complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases.
Inside Philip Morris’ controversial Vectura acquisition
The tobacco company’s buyout of a healthcare business has sparked both fury and confusion from campaigners and politicians.
Partners Group to acquire Pharmathen from BC Partners for $1.9bn
On acquisition, Partners Group will work to strengthen Pharmathen’s business in Europe and the US.
